Bile Acid Changes After High-Dose Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis: Relation to Disease Progression
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
High-dose (28-30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve survival and is associated with increased rates of serious adverse events. The mechanism for the latter undesired effect remains unclear. High-dose UDCA could result in the production of hepatotoxic bile acids, such as lithocholic acid (LCA), because of limited small bowel absorption of UDCA and conversion of UDCA by bacteria in the colon. We determined the serum bile acid composition in 56 patients with PSC previously enrolled in a randomized, double-blind controlled trial of high-dose UDCA versus placebo. Samples for analysis were obtained at the baseline and at the end of treatment. The mean changes in the UDCA level (16.86 versus 0.05 μmol/L) and total bile acid level (17.21 versus −0.55 μmol/L) were significantly higher in the UDCA group (n = 29) versus the placebo group (n = 27) when pretreatment levels were compared ( P < 0.0001). LCA was also markedly increased (0.22 versus 0.01 μmol/L) in the UDCA group compared to the placebo group ( P = 0.001). No significant changes were detected for cholic acid, deoxycholic acid, or chenodeoxycholic acid. Patients (n = 9) in the UDCA group who reached clinical endpoints of disease progression (the development of cirrhosis, varices, liver transplantation, or death) tended to have greater increases in their posttreatment total bile acid levels (34.99 versus 9.21 μmol/L, P < 0.08) in comparison with those who did not. Conclusion: High-dose UDCA treatment in PSC patients results in marked UDCA enrichment and significant expansion of the total serum bile acid pool, including LCA. Hepatology 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Self-citationOlsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.017 · Cited by 394
Self-citationHigh-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03777.x · Cited by 242
Self-citationCullen, S. N., Rust, C., Fleming, K., Edwards, C., Beuers, U., & Chapman, R. W. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.12.023 · Cited by 136
Cited by
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 592
Self-citationDiversification of host bile acids by members of the gut microbiota
Winston, J. A., & Theriot, C. M. (2020) · Gut Microbes · doi:10.1080/19490976.2019.1674124 · Cited by 587
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Eaton, J. E., Silveira, M. G., Pardi, D. S., Sinakos, E., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., et al. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.156 · Cited by 268
Self-citationAllegretti, J. R., Kassam, Z., Carrellas, M., Mullish, B. H., Marchesi, J. R., Pechlivanis, A., Smith, M., Gerardin, Y., Timberlake, S., Pratt, D. S., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000115 · Cited by 234
The features of mucosa‐associated microbiota in primary sclerosing cholangitis
Torres, J., Bao, X., Goel, A., Colombel, J. ‐., Pekow, J., Jabri, B., Williams, K. M., Castillo, A., Odin, J. A., Meckel, K., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13552 · Cited by 149
Rossen, N. G., Fuentes, S., Boonstra, K., D’Haens, G. R., Heilig, H. G., Zoetendal, E. G., de Vos, W. M., & Ponsioen, C. Y. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jju023 · Cited by 129
Singh, S., Khanna, S., Pardi, D. S., Loftus, E. V., & Talwalkar, J. A. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318286fa61 · Cited by 94
The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts
Hov, J., & Karlsen, T. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1608801 · Cited by 65
Cholestatic phenotypes of autoimmune hepatitis
Czaja, A. J. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.08.039 · Cited by 63
Hasan, M. N., Chen, J., Wang, H., Du, Y., Clayton, Y. D., Gu, L., & Li, T. (2023) · Cells · doi:10.3390/cells12101371 · Cited by 16
Metadata
- Authors
- Sinakos, E., Marschall, H.-U., Kowdley, K. V., Befeler, A., Keach, J., & Lindor, K.
- Venue
- Hepatology
- Published
- 2010-07
- Volume
- 52
- Issue
- 1
- Pages
- 197-203
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1982014243
- Cited by
- 119
- References
- 4
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.